Top

Published in:

01-12-2017 | Letter

SGLT2 inhibitors and cancer: why further evidence is required

Author: Altamash M. Y. Shaikh

Published in: Diabetologia | Issue 12/2017

Excerpt

To the Editor: The article on sodium–glucose cotransporter 2 (SGLT2) inhibitors and cancers by Tang et al [1], which was recently published in Diabetologia, is very relevant to practice in today’s world. However, this letter is to bring to your kind attention an error in this article. Tang and colleagues conducted a meta-analysis of RCTs to identify any risk of cancer with SGLT2 inhibitors. The results suggested a possible increased risk of bladder cancer with empagliflozin therapy. We noted a possible error in the paper, as discussed below. …

Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. https://doi.org/10.1007/s00125-017-4370-8

Zinman B, Wanner C, Lachin JM (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM 373:2117–2128CrossRefPubMed

US Food and Drug Administration (2016) FDA briefing document: Endocrine and Metabolic Drug Advisory Committee meeting. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf. Accessed 31 August 2017

Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111–E4119CrossRefPubMedPubMedCentral

Lin H-W, Tseng C-H (2014) A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. https://doi.org/10.1155/2014/719578

Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K (2015) Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther 6:357–375CrossRefPubMedPubMedCentral

Title: SGLT2 inhibitors and cancer: why further evidence is required
Author: Altamash M. Y. Shaikh
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 12/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-017-4434-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

SGLT2 inhibitors and cancer: why further evidence is required

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2017

Europe has to step up its efforts to produce innovative and safe diabetes technology

South Asian men have lower expression of IFN signalling genes in white adipose tissue and skeletal muscle compared with white men

Glucose effectiveness, but not insulin sensitivity, is improved after short-term interval training in individuals with type 2 diabetes mellitus: a controlled, randomised, crossover trial

Osteomyelitis of the foot: non-surgical management, SPECT/CT scanning and minimising the duration of antibiotic use

Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes

Termination of pregnancy and sterilisation in women with childhood-onset type 1 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page